Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
10:20am, Tuesday, 29'th Mar 2022 Zacks Investment Research
Smart Beta ETF report for XPH
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
10:20am, Tuesday, 29'th Mar 2022 Zacks Investment Research
Smart Beta ETF report for PJP
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
09:45pm, Monday, 28'th Mar 2022 Zacks Investment Research
Merck (MRK) closed the most recent trading day at $81.21, moving -0.16% from the previous trading session.
Bristol (BMY) Label Expansion of Reblozyl Delayed by 3 Months
03:56pm, Monday, 28'th Mar 2022 Zacks Investment Research
Bristol Myers (BMY) application seeking label expansion of Reblozy extended by three months by the FDA.
FDA Revises EUA of Glaxo (GSK) & Vir's (VIR) COVID Therapy
03:41pm, Monday, 28'th Mar 2022 Zacks Investment Research
The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a d
AstraZeneca's (AZN) Imfinzi Misses Goal in Cervical Cancer Study
06:24pm, Friday, 25'th Mar 2022 Zacks Investment Research
AstraZeneca's (AZN) blockbuster drug Imfinzi fails to achieve progression-free survival endpoint with statistical significance in cervical cancer patients during a late-stage study.
Bristol Myers (BMY) Gains 16% YTD: Will the Momentum Continue?
03:49pm, Friday, 25'th Mar 2022 Zacks Investment Research
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.
The Zacks Analyst Blog Highlights Novartis, Merck and Pfizer
10:35am, Friday, 25'th Mar 2022 Zacks Investment Research
Novartis, Merck and Pfizer have been included in this Analyst Blog.
Pharma Stock Roundup: NVS, MRK Get FDA Nod, PFE Ulcerative Colitis Study Succeeds
02:14pm, Thursday, 24'th Mar 2022 Zacks Investment Research
FDA approves Novartis' (NVS) Pluvicto for a certain type of advanced prostate cancer and Merck's (MRK) Keytruda for expanded use in endometrial carcinoma. Pfizer's (PFE) late-stage ulcerative colitis
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Novartis Announces FDA Approval Of Prostate Cancer Drug Pluvicto
Novartis AG (NYSE: NVS) said the U.S.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
02:00pm, Wednesday, 23'rd Mar 2022 Zacks Investment Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merck (MRK) Gains But Lags Market: What You Should Know
09:45pm, Tuesday, 22'nd Mar 2022 Zacks Investment Research
Merck (MRK) closed at $79.30 in the latest trading session, marking a +0.3% move from the prior day.
Merck (MRK) Keytruda Gets Another FDA Nod in Endometrial Cancer
04:06pm, Tuesday, 22'nd Mar 2022 Zacks Investment Research
Merck's (MRK) Keytruda gets approval for advanced endometrial carcinoma therapy in certain patients who are not suited for curative surgery or radiation.
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
12:31pm, Tuesday, 22'nd Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Merck's Keytruda Monotherapy Approved For A Type Of Endometrial Cancer
Merck & Co., Inc. (NYSE: MRK) s
Bristol Myers' (BMY) Opdualag Wins FDA Nod for Melanoma
03:23pm, Monday, 21'st Mar 2022 Zacks Investment Research
Bristol Myers (BMY) gets FDA approval for a fixed-dose combination of Opdivo (nivolumab) and relatlimab to treat patients 12 years of age or older with unresectable or metastatic melanoma.
